Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cell Signaling in Plants01:25

Cell Signaling in Plants

5.7K
Plant cells communicate to coordinate their cycle of growth, flowering and fruiting, and activities in roots, shoots, and leaves in response to the changing environmental conditions. Plant signaling is distinct from animal signaling. Plants primarily utilize enzyme-linked receptors, whereas the largest class of cell-surface receptors in animals are G-protein coupled receptors (GPCRs). Unlike animals, receptor tyrosine kinases are rare in plants. Instead, plants have a diverse class of...
5.7K
GPCR Desensitization01:12

GPCR Desensitization

6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

12.4K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

<sup>18</sup>F-fluciclovine positron emission tomography uptake is not exclusive to malignant brain tumors: Two cases of low-grade and benign lesions with detailed pathological findings.

Surgical neurology international·2026
Same author

Crystalglobulin-Induced Nephropathy and Cardiac Nonamyloidotic Immunoglobulin Deposition Disease: A Fatal Case Report.

Kidney medicine·2026
Same author

Technical principles of watertight dural closure in endoscopic endonasal surgery: How I do it.

Acta neurochirurgica·2026
Same author

Interactions between atomic-scale skyrmions in 2D chiral magnets.

Scientific reports·2026
Same author

Complete Remission After Percutaneous Renal Artery Angioplasty for Focal Segmental Glomerulosclerosis due to Takayasu Disease: A Case Report.

Kidney medicine·2026
Same author

Observation of the Einstein-de Haas effect in a Bose-Einstein condensate.

Science (New York, N.Y.)·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K

[Receptor Aβ PirB y su regulación por LOTUS]

Yuki Kawaguchi1, Kohtaro Takei1

  • 1Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine.

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
|August 31, 2025
PubMed
Resumen

Los investigadores identificaron un nuevo objetivo farmacológico para el tratamiento de la enfermedad de Alzheimer (EA). El receptor B pareado de inmunoglobulina (PirB) y su regulador LOTUS muestran potencial para mejorar la función cognitiva y combatir la patología de la EA.

Más Videos Relacionados

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K
Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

Área de la Ciencia:

  • La neurociencia
  • Farmacología
  • La bioquímica

Sus antecedentes:

  • La patogénesis de la enfermedad de Alzheimer (EA) se ha estudiado extensamente, pero los tratamientos efectivos siguen siendo elusivos.
  • El receptor pareado de inmunoglobulina B (PirB) es un receptor neuronal implicado en la regulación de la plasticidad y la respuesta a la beta amiloide (Aβ).

Objetivo del estudio:

  • Para explorar el PirB como un nuevo objetivo terapéutico para la EA.
  • Investigar el papel de la sustancia usher del tracto olfativo lateral (LOTUS) como inhibidor endógeno de PirB y su potencial en el tratamiento de la EA.

Principales métodos:

  • Revisión de la investigación existente sobre PirB, LOTUS y sus funciones en la plasticidad neuronal y la patología Aβ.
  • Análisis de la función de PirB como receptor Aβ y su impacto en la salud neuronal.

Principales resultados:

  • PirB actúa como un regulador negativo de la plasticidad neuronal; su inhibición mejora la plasticidad, la densidad de la columna vertebral y la función cognitiva.
  • PirB funciona como un receptor para Aβ, mediando la neurotoxicidad y la plasticidad reducida.
  • LOTUS, un antagonista endógeno de PirB, inhibe la neurotoxicidad inducida por Aβ.

Conclusiones:

  • PirB representa un objetivo prometedor y novedoso para la enfermedad de Alzheimer.
  • LOTUS, al inhibir la función del receptor Aβ de PirB, puede ofrecer beneficios terapéuticos contra la patología Aβ.